In SURMOUNT1, tirzepatide shifted body composition and cardiometabolic markers in ways that support strength, mobility, and longterm resilience. Researchers from the SURMOUNT1 program found that tirzepatide was associated with: Average weight loss of about 1521% of starting body weight at higher doses Reductions in waist circumference of roughly 1420 cm, signaling less central and visceral fat About threequarters of weight lost coming from fat mass, with fat mass dropping by around onethird and lean mass by about 10% Meaningful drops in systolic blood pressure and atherogenic lipids, with more participants hitting combined goals for weight, blood pressure, and nonHDL cholesterol versus placebo Improved physical function scores on questionnaires, reflecting easier walking, stair climbing, and daily activity That pattern preferential fat loss, preserved muscle, a smaller waist, and better hemodynamics is exactly what protects balance, strength, and independence, making it one of the clearest ways tirzepatide can support a longer healthspan beyond a lower number on the scale
Significant weight loss results may take several months
Download a Free Sample To learn more about this report, Impact of Supply Chain Disruption on GLP-1 Receptor Agonist Market The GLP-1 receptor agonist market is highly exposed to supply chain disruptions because it relies on globally sourced active pharmaceutical ingredients, peptide manufacturing capacity, injectable delivery devices, sterile packaging materials, cold-chain logistics, and specialized production facilities that must comply with stringent regulatory standards
Are results guaranteed
A lukewarm shower feels scalding
This blog will walk through the basics in a positive, easytounderstand way and will point you back to Turbo-Tan for more indepth guides, FAQs, and uptodate information
